recombinant human soluble il 6r protein Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    R&D Systems recombinant human soluble il 6 receptor
    IL-17 Enhances <t>IL-6-mediated</t> SOCS3 Expression in Primary Astrocytes, and SOCS3 is a Negative Regulator of the Synergistic Effect of IL-6 and IL-17 A , Astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 2 - 8 h, and levels of SOCS3 mRNA expression were determined by QRT-PCR. B and C, Astrocytes were transfected with SOCS3 siRNA (100 nM) or siRNA control (100 nM) for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 4 h. Levels of SOCS3 (B) and IL-6 (C) mRNA expression was determined by QRT-PCR. D, Astrocytes were transfected with SOCS3 siRNA or siRNA control for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 24 h, and supernatants analyzed for IL-6 protein by ELISA. E, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were harvested. Digestion of genomic DNA distinguishes the full-length (fl) and excised alleles ( Δ ). F, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, the cells were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 4 h, and levels of IL-6 mRNA expression determined by QRT-PCR. G, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 16 or 24 h, and supernatants analyzed for IL-6 protein by ELISA. All data are the mean ± SD of three experiments. *, p ≤ 0.05;**, p ≤ 0.01.
    Recombinant Human Soluble Il 6 Receptor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human soluble il 6 receptor/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant human soluble il 6 receptor - by Bioz Stars, 2021-06
    94/100 stars
      Buy from Supplier

    94
    Thermo Fisher interleukin 6 receptor
    IL-17 Enhances <t>IL-6-mediated</t> SOCS3 Expression in Primary Astrocytes, and SOCS3 is a Negative Regulator of the Synergistic Effect of IL-6 and IL-17 A , Astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 2 - 8 h, and levels of SOCS3 mRNA expression were determined by QRT-PCR. B and C, Astrocytes were transfected with SOCS3 siRNA (100 nM) or siRNA control (100 nM) for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 4 h. Levels of SOCS3 (B) and IL-6 (C) mRNA expression was determined by QRT-PCR. D, Astrocytes were transfected with SOCS3 siRNA or siRNA control for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 24 h, and supernatants analyzed for IL-6 protein by ELISA. E, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were harvested. Digestion of genomic DNA distinguishes the full-length (fl) and excised alleles ( Δ ). F, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, the cells were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 4 h, and levels of IL-6 mRNA expression determined by QRT-PCR. G, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 16 or 24 h, and supernatants analyzed for IL-6 protein by ELISA. All data are the mean ± SD of three experiments. *, p ≤ 0.05;**, p ≤ 0.01.
    Interleukin 6 Receptor, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/interleukin 6 receptor/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    interleukin 6 receptor - by Bioz Stars, 2021-06
    94/100 stars
      Buy from Supplier

    91
    Abeomics human sil 6r recombinant protein
    Identification of cytokines regulated by soluble interleukin‐6 receptor (sIL‐6R) using an antibody array. (a) Inflammation‐related interleukins were detected using an inflammation antibody array after treatment with human <t>sIL‐6R</t> recombinant protein (40 ng/ml) and Helicobacter pylori (Hp) exosomes. rhsIL6R = recombinant human soluble IL‐6 receptor. (b) Neutralizing antibodies (40 ng/ml) were used to weaken the effect of sIL‐6R. sIL6R‐Nab = neutralizing antibodies against sIL‐6R.
    Human Sil 6r Recombinant Protein, supplied by Abeomics, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human sil 6r recombinant protein/product/Abeomics
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human sil 6r recombinant protein - by Bioz Stars, 2021-06
    91/100 stars
      Buy from Supplier

    93
    R&D Systems sil 6r alpha
    Identification of cytokines regulated by soluble interleukin‐6 receptor (sIL‐6R) using an antibody array. (a) Inflammation‐related interleukins were detected using an inflammation antibody array after treatment with human <t>sIL‐6R</t> recombinant protein (40 ng/ml) and Helicobacter pylori (Hp) exosomes. rhsIL6R = recombinant human soluble IL‐6 receptor. (b) Neutralizing antibodies (40 ng/ml) were used to weaken the effect of sIL‐6R. sIL6R‐Nab = neutralizing antibodies against sIL‐6R.
    Sil 6r Alpha, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sil 6r alpha/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sil 6r alpha - by Bioz Stars, 2021-06
    93/100 stars
      Buy from Supplier

    N/A
    This is a recombinant monoclonal antibody
      Buy from Supplier

    N/A
    sIL 6R Interleukin 6 Soluble Receptor Human Recombinant sIL 6R Human Recombinant produced in E Coli is a single non glycosylated polypeptide chain containing 338 amino acids 20 357 corresponding
      Buy from Supplier

    N/A
    The GABA Receptor Epsilon Antibody S413 67 HRP from Novus Biologicals is a mouse monoclonal antibody to GABA Receptor Epsilon This antibody reacts with human rat The GABA Receptor Epsilon
      Buy from Supplier

    Image Search Results


    IL-17 Enhances IL-6-mediated SOCS3 Expression in Primary Astrocytes, and SOCS3 is a Negative Regulator of the Synergistic Effect of IL-6 and IL-17 A , Astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 2 - 8 h, and levels of SOCS3 mRNA expression were determined by QRT-PCR. B and C, Astrocytes were transfected with SOCS3 siRNA (100 nM) or siRNA control (100 nM) for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 4 h. Levels of SOCS3 (B) and IL-6 (C) mRNA expression was determined by QRT-PCR. D, Astrocytes were transfected with SOCS3 siRNA or siRNA control for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 24 h, and supernatants analyzed for IL-6 protein by ELISA. E, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were harvested. Digestion of genomic DNA distinguishes the full-length (fl) and excised alleles ( Δ ). F, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, the cells were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 4 h, and levels of IL-6 mRNA expression determined by QRT-PCR. G, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 16 or 24 h, and supernatants analyzed for IL-6 protein by ELISA. All data are the mean ± SD of three experiments. *, p ≤ 0.05;**, p ≤ 0.01.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: IL-17 Enhances IL-6-mediated SOCS3 Expression in Primary Astrocytes, and SOCS3 is a Negative Regulator of the Synergistic Effect of IL-6 and IL-17 A , Astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 2 - 8 h, and levels of SOCS3 mRNA expression were determined by QRT-PCR. B and C, Astrocytes were transfected with SOCS3 siRNA (100 nM) or siRNA control (100 nM) for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 4 h. Levels of SOCS3 (B) and IL-6 (C) mRNA expression was determined by QRT-PCR. D, Astrocytes were transfected with SOCS3 siRNA or siRNA control for 48 h. Transfected cells were then treated with medium (UN) or IL-6/R plus IL-17 for 24 h, and supernatants analyzed for IL-6 protein by ELISA. E, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were harvested. Digestion of genomic DNA distinguishes the full-length (fl) and excised alleles ( Δ ). F, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, the cells were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 4 h, and levels of IL-6 mRNA expression determined by QRT-PCR. G, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 16 or 24 h, and supernatants analyzed for IL-6 protein by ELISA. All data are the mean ± SD of three experiments. *, p ≤ 0.05;**, p ≤ 0.01.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Expressing, Quantitative RT-PCR, Transfection, Enzyme-linked Immunosorbent Assay, Infection, Incubation

    Proposed Model of IL-17 Enhancement of the IL-6 Signaling Cascade in Astrocytes A, IL-6/R and IL-17 activate the NF-κB and MAPK pathway, which then induce IL-6 gene expression. The synergistic effect of these two mediators depends on NF-κB, p38 and JNK MAPK activity. Activated NF-κB p65, c-Fos and c-Jun bind to the IL-6 promoter. Concurrent with NF-κB and MAPK recruitment, IL-6/R and IL-17 leads to the recruitment of coactivators CBP and p300, modifications in AcH3 and AcH4, and recruitment of RNA Pol II to the IL-6 promoter, which results in transcriptional activation of the IL-6 gene. IL-17 can also enhance IL-6/R induced SOCS3 expression, and SOCS3 inhibits IL-6/R plus IL-17-induced NF-κB and MAPK activation, which results in a reduction of IL-6 gene expression in astrocytes. B , Naive CD4 + T cells, after activation by signaling through the T cell receptor and co-stimulatory molecules, can differentiate into Th17 cells in the presence of IL-6, TGF-β, IL-1 and IL-23. IL-17 together with IL-6/R triggers a positive-feedforward loop of IL-6 expression in astrocytes, which may also influence Th17 cell differentiation. SOCS3 participates in these processes as a negative feedback regulator. See text for details.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: Proposed Model of IL-17 Enhancement of the IL-6 Signaling Cascade in Astrocytes A, IL-6/R and IL-17 activate the NF-κB and MAPK pathway, which then induce IL-6 gene expression. The synergistic effect of these two mediators depends on NF-κB, p38 and JNK MAPK activity. Activated NF-κB p65, c-Fos and c-Jun bind to the IL-6 promoter. Concurrent with NF-κB and MAPK recruitment, IL-6/R and IL-17 leads to the recruitment of coactivators CBP and p300, modifications in AcH3 and AcH4, and recruitment of RNA Pol II to the IL-6 promoter, which results in transcriptional activation of the IL-6 gene. IL-17 can also enhance IL-6/R induced SOCS3 expression, and SOCS3 inhibits IL-6/R plus IL-17-induced NF-κB and MAPK activation, which results in a reduction of IL-6 gene expression in astrocytes. B , Naive CD4 + T cells, after activation by signaling through the T cell receptor and co-stimulatory molecules, can differentiate into Th17 cells in the presence of IL-6, TGF-β, IL-1 and IL-23. IL-17 together with IL-6/R triggers a positive-feedforward loop of IL-6 expression in astrocytes, which may also influence Th17 cell differentiation. SOCS3 participates in these processes as a negative feedback regulator. See text for details.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Expressing, Activity Assay, Activation Assay, Cell Differentiation

    IL-17 Synergizes with IL-6/R for Activation of the NF-κB and MAPK Pathways A , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 15 and 30 min, and then cell lysates were immunoblotted with antibodies against IκBα and GAPDH. The basal level of the untreated sample was set at 100, and the percentage change of IκBα upon IL-6/R, IL-17 or IL-6/R + IL-17 treatment compared with the basal value. B , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 30 and 60 min, and then cell lysates were immunoblotted with antibodies against phospho-p65 Ser 536, p65 and GAPDH. C , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 15 and 30 min, and then cell lysates were immunoblotted with antibodies against phospho-ERK1/2, ERK1/2 and GAPDH. D , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R and IL-17 for 30 min and 60 min, and then cell lysates were immunoblotted with antibodies against phospho-p38, p38 and GAPDH. E , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 30 and 60 min, and then cell lysates were immunoblotted with antibodies against phospho-JNK, JNK and GAPDH. The basal level of the untreated sample was set at 1.0 and fold activation upon IL-6/R, IL-17 or IL-6/R + IL-17 treatment was compared with that value ( B , C , D and E ). Representative of at least three experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: IL-17 Synergizes with IL-6/R for Activation of the NF-κB and MAPK Pathways A , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 15 and 30 min, and then cell lysates were immunoblotted with antibodies against IκBα and GAPDH. The basal level of the untreated sample was set at 100, and the percentage change of IκBα upon IL-6/R, IL-17 or IL-6/R + IL-17 treatment compared with the basal value. B , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 30 and 60 min, and then cell lysates were immunoblotted with antibodies against phospho-p65 Ser 536, p65 and GAPDH. C , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 15 and 30 min, and then cell lysates were immunoblotted with antibodies against phospho-ERK1/2, ERK1/2 and GAPDH. D , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R and IL-17 for 30 min and 60 min, and then cell lysates were immunoblotted with antibodies against phospho-p38, p38 and GAPDH. E , Astrocytes were incubated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 30 and 60 min, and then cell lysates were immunoblotted with antibodies against phospho-JNK, JNK and GAPDH. The basal level of the untreated sample was set at 1.0 and fold activation upon IL-6/R, IL-17 or IL-6/R + IL-17 treatment was compared with that value ( B , C , D and E ). Representative of at least three experiments.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Activation Assay, Incubation

    IL-17 and IL-6/R Induction of IL-6 Depends on NF-κB, p38 and JNK MAPK Activity A , Astrocytes were cultured in absence or presence of IL-17 followed by IL-6/R treatment for 4 h. Actinomycin D (5 ng/ml) was then added, and cells harvested at 0, 30, 60, 120, and 240 min after addition. The abundance of IL-6 mRNA was determined by QRT-PCR. B , C , DMSO vehicle, BAY 11 (5 μM), U0126 (10 μM), SB203580 (10 μM) or JNKi II (10 μM) were added to cultures 1 h before cytokine addition, and then astrocytes were incubated with medium, IL-6/R, IL-17 or IL-6/R plus IL-17 for 4 h. Levels of IL-6 mRNA expression were determined by QRT-PCR. All data are the mean ± SD of three experiments. **, p ≤ 0.01; NS = not significant.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: IL-17 and IL-6/R Induction of IL-6 Depends on NF-κB, p38 and JNK MAPK Activity A , Astrocytes were cultured in absence or presence of IL-17 followed by IL-6/R treatment for 4 h. Actinomycin D (5 ng/ml) was then added, and cells harvested at 0, 30, 60, 120, and 240 min after addition. The abundance of IL-6 mRNA was determined by QRT-PCR. B , C , DMSO vehicle, BAY 11 (5 μM), U0126 (10 μM), SB203580 (10 μM) or JNKi II (10 μM) were added to cultures 1 h before cytokine addition, and then astrocytes were incubated with medium, IL-6/R, IL-17 or IL-6/R plus IL-17 for 4 h. Levels of IL-6 mRNA expression were determined by QRT-PCR. All data are the mean ± SD of three experiments. **, p ≤ 0.01; NS = not significant.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Activity Assay, Cell Culture, Quantitative RT-PCR, Incubation, Expressing

    IL-6/R plus IL-17 Enhances Recruitment of p65, P-p65, c-Jun, c-Fos, CBP, p300, and RNA Pol II to the IL-6 Promoter A, Primary astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 90 min, and then cells were cross-linked with formaldehyde. Soluble chromatin was subjected to immunoprecipitation with Abs against p65, P-p65, c-Fos, c-Jun, or normal rabbit IgG. PCR analysis of the positive control (input) indicates that soluble chromatin samples obtained from each time point had equal amounts of chromatin fragments containing the IL-6 promoter. B, Primary astrocytes were treated as above. Soluble chromatin was subjected to immunoprecipitation with Abs against histone acetylation (Ac-H3 and Ac-H4), p300, CBP, RNA Pol II or normal rabbit IgG. The basal level of the untreated sample was set at 1.0 and fold activation upon IL-6/R, IL-17 or IL-6/R plus IL-17 treatment was compared with that value. Representative of at least three experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: IL-6/R plus IL-17 Enhances Recruitment of p65, P-p65, c-Jun, c-Fos, CBP, p300, and RNA Pol II to the IL-6 Promoter A, Primary astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 90 min, and then cells were cross-linked with formaldehyde. Soluble chromatin was subjected to immunoprecipitation with Abs against p65, P-p65, c-Fos, c-Jun, or normal rabbit IgG. PCR analysis of the positive control (input) indicates that soluble chromatin samples obtained from each time point had equal amounts of chromatin fragments containing the IL-6 promoter. B, Primary astrocytes were treated as above. Soluble chromatin was subjected to immunoprecipitation with Abs against histone acetylation (Ac-H3 and Ac-H4), p300, CBP, RNA Pol II or normal rabbit IgG. The basal level of the untreated sample was set at 1.0 and fold activation upon IL-6/R, IL-17 or IL-6/R plus IL-17 treatment was compared with that value. Representative of at least three experiments.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Immunoprecipitation, Polymerase Chain Reaction, Positive Control, Activation Assay

    Enhanced Activation of NF-κB and MAPK Pathways in SOCS3 Deficient Astrocytes To evaluate NF-κB and MAPK activation in the absence or presence of SOCS3, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were treated with medium (UN) or IL-6/R plus IL-17 for 15, 30, 60 or 120 min, and then cell lysates were immunoblotted with antibodies against phospho-p65 Ser 536, p65, phospho-p38, p38, phospho-JNK, JNK or GAPDH. The basal level of the untreated GFP infected sample was set at 1.0 and fold activation upon IL-6/R plus IL-17 treatment compared with that value. Representative of at least three experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: Enhanced Activation of NF-κB and MAPK Pathways in SOCS3 Deficient Astrocytes To evaluate NF-κB and MAPK activation in the absence or presence of SOCS3, SOCS3 floxed astrocytes were infected with GFP as control or GFP-Cre for deletion. After 48 h in culture, cells were treated with medium (UN) or IL-6/R plus IL-17 for 15, 30, 60 or 120 min, and then cell lysates were immunoblotted with antibodies against phospho-p65 Ser 536, p65, phospho-p38, p38, phospho-JNK, JNK or GAPDH. The basal level of the untreated GFP infected sample was set at 1.0 and fold activation upon IL-6/R plus IL-17 treatment compared with that value. Representative of at least three experiments.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Activation Assay, Infection

    IL-17 Enhances IL-6/sIL-6R-mediated IL-6 Expression in Primary Astrocytes A , IL-17RA and IL-17RC mRNA expression was determined by RT-PCR in RAW264.7 cells (positive control), and primary astrocytes, in duplicate. B , Primary astrocytes were treated with medium (UN), IL-6/R (IL-6, 10 ng/ml and sIL-6R, 25 ng/ml), IL-17 (25 ng/ml) or IL-6/R plus IL-17 for up to 24 h, and levels of IL-6 and GAPDH mRNA expression were determined by RT-PCR and QRT-PCR. C , Primary astrocytes were treated with medium (UN), IL-6/R, different concentrations of IL-17 (1-50 ng/ml) or IL-6/R + IL-17 (1-50 ng/ml) for 4 h, and levels of IL-6 mRNA expression were determined by QRT-PCR. D , Primary astrocytes were treated with medium (UN), IL-6, sIL-6R or IL-17 in various combinations for 4 h, and levels of IL-6 mRNA expression were determined by QRT-PCR. E , Primary astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 2 - 48 h, and supernatants were analyzed for IL-6 protein using ELISA. Experiments shown are representative of at least three experiments. All data are the mean ± SD of three experiments. *, p ≤0.05; **, p ≤0.01.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: Interleukin-17 Enhancement of the Interleukin-6 Signaling Cascade in Astrocytes

    doi: 10.4049/jimmunol.1000142

    Figure Lengend Snippet: IL-17 Enhances IL-6/sIL-6R-mediated IL-6 Expression in Primary Astrocytes A , IL-17RA and IL-17RC mRNA expression was determined by RT-PCR in RAW264.7 cells (positive control), and primary astrocytes, in duplicate. B , Primary astrocytes were treated with medium (UN), IL-6/R (IL-6, 10 ng/ml and sIL-6R, 25 ng/ml), IL-17 (25 ng/ml) or IL-6/R plus IL-17 for up to 24 h, and levels of IL-6 and GAPDH mRNA expression were determined by RT-PCR and QRT-PCR. C , Primary astrocytes were treated with medium (UN), IL-6/R, different concentrations of IL-17 (1-50 ng/ml) or IL-6/R + IL-17 (1-50 ng/ml) for 4 h, and levels of IL-6 mRNA expression were determined by QRT-PCR. D , Primary astrocytes were treated with medium (UN), IL-6, sIL-6R or IL-17 in various combinations for 4 h, and levels of IL-6 mRNA expression were determined by QRT-PCR. E , Primary astrocytes were treated with medium (UN), IL-6/R, IL-17 or IL-6/R plus IL-17 for 2 - 48 h, and supernatants were analyzed for IL-6 protein using ELISA. Experiments shown are representative of at least three experiments. All data are the mean ± SD of three experiments. *, p ≤0.05; **, p ≤0.01.

    Article Snippet: Recombinant human IL-6, recombinant human soluble IL-6 Receptor (sIL-6R) and recombinant mouse IL-17 were from R & D Systems (Minneapolis, MN).

    Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Positive Control, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

    Identification of cytokines regulated by soluble interleukin‐6 receptor (sIL‐6R) using an antibody array. (a) Inflammation‐related interleukins were detected using an inflammation antibody array after treatment with human sIL‐6R recombinant protein (40 ng/ml) and Helicobacter pylori (Hp) exosomes. rhsIL6R = recombinant human soluble IL‐6 receptor. (b) Neutralizing antibodies (40 ng/ml) were used to weaken the effect of sIL‐6R. sIL6R‐Nab = neutralizing antibodies against sIL‐6R.

    Journal: Clinical and Experimental Immunology

    Article Title: Serum exosomes of chronic gastritis patients infected with Helicobacter pylori mediate IL‐1α expression via IL‐6 trans‐signalling in gastric epithelial cells

    doi: 10.1111/cei.13200

    Figure Lengend Snippet: Identification of cytokines regulated by soluble interleukin‐6 receptor (sIL‐6R) using an antibody array. (a) Inflammation‐related interleukins were detected using an inflammation antibody array after treatment with human sIL‐6R recombinant protein (40 ng/ml) and Helicobacter pylori (Hp) exosomes. rhsIL6R = recombinant human soluble IL‐6 receptor. (b) Neutralizing antibodies (40 ng/ml) were used to weaken the effect of sIL‐6R. sIL6R‐Nab = neutralizing antibodies against sIL‐6R.

    Article Snippet: Lipopolysaccharide (LPS) ( Escherichia coli 0111:B4; Sigma, St Louis, MO, USA), a tumour necrosis factor (TNF)‐α protease inhibitor (TAPI; Santa Cruz Biotechnology, Santa Cruz, CA, USA), exosomes from serum (100 μg/ml Hp or control exosomes), human sIL‐6R recombinant protein (rhsIL‐6R; Abeomics, Newmarket, UK) and the human IL‐6R alpha antibody (R & D Systems, Minneapolis, MN, USA) were used to stimulate the cells at suitable concentrations depending on the experimental needs.

    Techniques: Ab Array, Recombinant